|
1
|
Follicular Lymphoma, Pamphlet. Lymphoma
Association; 2017
|
|
2
|
Abd El-Ghaffar HA, Shamaa S, Attwan N, et
al: Stratification of Patients with Follicular Lymphoma.
IntechOpen; Rijeka: 2012, https://www.intechopen.com/books/hematology-science-and-practice/stratification-of-patients-with-follicular-lymphoma.
Accessed March 2, 2012.
|
|
3
|
Kridel R, Sehn LH and Gascoyne RD:
Pathogenesis of follicular lymphoma. J Clin Invest. 122:3424–3431.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bisikirska B, Bansal M, Shen Y,
Teruya-Feldstein J, Chaganti R and Califano A: Elucidation and
pharmacological targeting of novel molecular drivers of follicular
lymphoma progression. Cancer Res. 76:664–674. 2016. View Article : Google Scholar :
|
|
5
|
Katzenberger T, Kalla J, Leich E,
Stöcklein H, Hartmann E, Barnickel S, Wessendorf S, Ott MM,
Müller-Hermelink HK, Rosenwald A and Ott G: A distinctive subtype
of t(14;18)-negative nodal follicular non-Hodgkin lymphoma
characterized by a predominantly diffuse growth pattern and
deletions in the chromosomal region 1p-36. Blood. 113:1053–1061.
2009. View Article : Google Scholar
|
|
6
|
Casulo C, Burack WR and Friedberg JW:
Transformed follicular non-Hodgkin lymphoma. Blood. 125:40–47.
2015. View Article : Google Scholar
|
|
7
|
Christie L, Kernohan N, Levison D, Sales
M, Cunningham J, Gillespie K, Batstone P, Meiklejohn D and Goodlad
J: C-MYC translocation in t(14;18) positive follicular lymphoma at
presentation: An adverse prognostic indicator? Leuk Lymphoma.
49:470–476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bakhski A, Jensen JP, Goldman P, Wright
JJ, McBride OW, Epstein AL and Korsmeyer SJ: Cloning the
chromosomal break-point of t(14;18) human lymphomas: Clustering
around Jh on chromosome 14 and near a transcriptional unit on 18.
Cell. 41:899–906. 1985. View Article : Google Scholar
|
|
9
|
Tsujimoto Y, Gorham J, Cossman J, Jaffe E
and Croce CM: The t(14;18) chromosome translocations involved in
B-cell neoplasms result from mistakes in VDJ joining. Science.
229:1390–1393. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cleary ML and Sklar J: Nucleotide sequence
of a t(14;18) chromosomal breakpoint in follicular lymphoma and
demonstration of a breakpoint-cluster region near a
transcriptionally active locus on chromosome 18. Proc Natl Acad Sci
USA. 82:7439–7443. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsujimoto Y, Finger LR, Yunis J, Nowell PC
and Croce CM: Cloning of the chromosome breakpoint of neoplastic B
cells with the t(14;18) chromosome translocation. Science.
226:1097–1099. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Graninger WB, Seto M, Boutain B, Goldman P
and Korsmeyer SJ: Expression of Bcl-2 and Bcl-2-Ig fusion
transcripts in normal and neoplastic cells. J Clin Invest.
80:1512–1515. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Godon A, Moreau A, Talmant P,
Baranger-Papot L, Geneviéve F, Milpied N, Zandecki M and
Avet-Loiseau H: Is t(14;18)(q32;q21) a constant finding in
follicular lymphoma? An interphase FISH study on 63 patients
Leukemia. 17:255–259. 2003.
|
|
14
|
Husson H, Carideo EG, Neuberg D, Schultze
J, Munoz O, Marks PW, Donovan JW, Chillemi AC, O'Connell P and
Freedman AS: Gene expression profiling of follicular lymphoma and
normal germinal center B cells using cDNA arrays. Blood.
99:282–289. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Masir N, Campbell LJ, Goff LK, Jones M,
Marafioti T, Cordell J, Clear AJ, Lister TA, Mason DY and Lee AM:
BCL2 protein expression in follicular lymphomas with t(14;18)
chromosomal translocations. Br J Haematol. 144:716–725. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Staudt LM: A closer look at follicular
lymphoma. N Engl J Med. 356:741–742. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roulland S, Kelly RS, Morgado E, Sungalee
S, Solal-Celigny P, Colombat P, Jouve N, Palli D, Pala V, Tumino R,
et al: t(14;18) Translocation: A predictive blood biomarker for
follicular lymphoma. J Clin Oncol. 32:1347–1355. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Graham C and LeBrun DP: Tumor suppressors
in follicular lymphoma. Leuk Lymphoma. 56:1981–1988. 2015.
View Article : Google Scholar
|
|
19
|
Gu K, Fu K, Jain S, Liu Z, Iqbal J, Li M,
Sanger WG, Weisenburger DD, Greiner TC, Aoun P, et al:
t(14;18)-negative follicular lymphomas are associated with a high
frequency of BCL6 rearrangement at the alternative breakpoint
region. Mod Pathol. 22:1251–1257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Küppers R and Dalla-Favera R: Mechanisms
of chromosomal translocations in B cell lymphomas. Oncogene.
20:5580–5594. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Horsman DE, Okamoto I, Ludkovski O, Le N,
Harder L, Gesk S, Siebert R, Chhanabhai M, Sehn L, Connors JM and
Gascoyne RD: Follicular lymphoma lacking the t(14;18)(q32;q21):
Identification of two disease subtypes. Br J Haematol. 120:424–433.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vitolo U, Ferreri AJ and Montoto S:
Follicular lymphomas. Crit Rev Oncol Hematol. 66:248–261. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD and Jaffe ES: The 2016 revision of theWorld Health Organization
classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Samsi S, Lozanski G, Shana'ah A,
Krishanmurthy AK and Gurcan MN: Detection of follicles from
IHC-stained slides of follicular lymphoma using iterative
watershed. IEEE Trans Biomed Eng. 57:2609–2612. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paik PK, Johnson ML, D'Angelo SP, Sima CS,
Ang D, Dogan S, Miller VA, Ladanyi M, Kris MG and Riely GJ: Driver
mutations determine survival in smokers and never-smokers with
stage IIIB/IV lung adenocarcinomas. Cancer. 118:5840–5847. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Katzenberger T, Ott G, Klein T, Kalla J,
Müller-Hermelink HK and Ott MM: Cytogenetic alterations affecting
BCL6 are predominantly found in follicular lymphomas grade 3B with
a diffuse large B-cell component. Am J Pathol. 165:481–490. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ott G, Katzenberger T, Lohr A,
Kindelberger S, Rüdiger T, Wilhelm M, Kalla J, Rosenwald A, Müller
JG, Ott MM and Müller-Hermelink HK: Cytomorphologic,
immunohistochemical, and cytogenetic profiles of follicular
lymphoma: 2 types of follicular lymphoma grade 3. Blood.
99:3806–3812. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Horn H, Schmelter C, Leich E, Salaverria
I, Katzenberger T, Ott MM, Kalla J, Romero M, Siebert R, Rosenwald
A and Ott G: Follicular lymphoma grade 3B is a distinct neoplasm
according to cytogenetic and immunohistochemical profiles.
Haematologica. 96:1327–1334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Salaverria I and Siebert R: Follicular
lymphoma grade 3B. Best Pract Res Clin Haematol. 24:111–119. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bosga-Bouwer AG, van Imhoff GW, Boonstra
R, van der Veen A, Haralambieva E, van den Berg A, Jong B, Krause
V, Palmer MC, Coupland R, et al: Follicular lymphoma grade 3B
includes 3 cytogenetically defined subgroups with primary t(14;18),
3q27, or other translocations: t(14;18) and 3q27 are mutually
exclusive. Blood. 101:1149–1154. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shustik J, Han G, Farinha P, Johnson NA,
Ben Neriah S, Connors JM, Sehn LH, Horsman DE, Gascoyne RD and
Steidl C: Correlations between BCL6 rearrangement and outcome in
patients with diffuse large B-cell lymphoma treated with CHOP or
R-CHOP. Haematologica. 95:96–101. 2010. View Article : Google Scholar :
|
|
32
|
Vaandrager JW, Schuuring E, Raap T,
Philippo K, Kleiverda K and Kluin P: Interphase FISH detection of
BCL2 rearrangement in follicular lymphoma using breakpoint-flanking
probes. Genes Chromosomes Cancer. 27:85–94. 2000. View Article : Google Scholar
|
|
33
|
Weinberg OK, Ai WZ, Mariappan MR, Shum C,
Levy R and Arber DA: 'Minor' BCL2 breakpoints in follicular
lymphoma: Frequency and correlation with grade and disease
presentation in 236 cases. J Mol Diagn. 9:530–537. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leich E, Salaverria I, Bea S, Zettl A,
Wright G, Moreno V, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, et
al: Follicular lymphomas with and without translocation t(14;18)
differ in gene expression profiles and genetic alterations. Blood.
114:826–834. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Leich E, Zamo A, Horn H, Haralambieva E,
Puppe B, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, Weisenburger
DD, et al: MicroRNA profiles of t(14;18)-negative follicular
lymphoma support a late germinal center B-cell phenotype. Blood.
118:5550–5558. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schraders M, de Jong D, Kluin P, Groenen P
and van Krieken H: Lack of Bcl-2 expression in follicular lymphoma
may be caused by mutations in the BCL2 gene or by absence of the
t(14;18) translocation. J Pathol. 205:329–335. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Skinnider BF, Horsman DE, Dupuis B and
Gascoyne RD: Bcl-6 and Bcl-2 protein expression in diffuse large
B-cell lymphoma and follicular lymphoma: Correlation with 3q27 and
18q21 chromosomal abnormalities. Hum Pathol. 30:803–808. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo Y, Karube K, Kawano R, Suzumiya J,
Takeshita M, Kikuchi M, Huang GS, Li Q and Ohshima K: Bcl2-negative
follicular lymphomas frequently have Bcl6 translocation and/or Bcl6
or p53 expression. Pathol Int. 57:148–152. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jardin F, Gaulard P, Buchonnet G,
Contentin N, Lepretre S, Lenain P, Stamatoullas A, Picquenot JM,
Duval C, Parmentier F, et al: Follicular lymphoma without t(14;18)
and with BCL-6 rearrangement: A lymphoma subtype with distinct
pathological, molecular and clinical characteristics. Leukemia.
16:2309–2317. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gollub W, Stassek B, Huckhagel T, Bernd
HW, Krokowski M, Merz H, Feller AC and Thorns C:
BCL6-translocations affect the phenotype of follicular lymphomas
only in the absence of t(14;18)IgH/BCL2. Anticancer Res.
29:4649–4655. 2009.PubMed/NCBI
|
|
41
|
Pan Y, Meng B, Sun B, Guan B, Liang Y,
Wang H, Hao X and Fu K: Frequencies of BCL2 and BCL6 translocations
in representative Chinese follicular lymphoma patients:
Morphologic, immunohistochemical, and FISH analyses. Diagn Mol
Pathol. 21:234–240. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Karube K, Guo Y, Suzumiya J, Sugita Y,
Nomura Y, Yamamoto K, Shimizu K, Yoshida S, Komatani H, Takeshita
M, et al: CD10-MUM1 + follicular lymphoma lacks BCL2 gene
translocation and shows characteristic biologic and clinical
features. Blood. 109:3076–3079. 2007. View Article : Google Scholar
|
|
43
|
Gagyi E, Balogh Z, Bödör C, Timár B,
Reiniger L, Deák L, Csomor J, Csernus B, Szepesi A and Matolcsy A:
Somatic hyper-mutation of IGVH genes and aberrant somatic
hypermutation in follicular lymphoma without BCL-2 gene
rearrangement and expression. Haematologica. 93:1822–1828. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu Q, Salaverria I, Pittaluga S, Jegalian
AG, Xi L, Siebert R, Raffeld M, Hewitt SM and Jaffe ES: Follicular
lymphomas in children and young adults: A comparison of the
pediatric variant with usual follicular lymphoma. Am J Surg Pathol.
37:333–343. 2013. View Article : Google Scholar :
|
|
45
|
Martin-Guerrero I, Salaverria I, Burkhardt
B, Szczepanowski M, Baudis M, Bens S, de Leval L, Garcia-Orad A,
Horn H, Lisfeld J, et al: Recurrent loss of heterozygosity in 1p36
associated with TNFRSF14 mutations in IRF4 translocation negative
pediatric follicular lymphomas. Haematologica. 98:1237–1241. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jaffe ES: The 2008 WHO classification of
lymphomas: Implications for clinical practice and translational
research. Hematol Am Soc Hematol Educ Program. 523–531. 2009.
View Article : Google Scholar
|
|
47
|
Louissaint A Jr, Ackerman AM,
Dias-Santagata D, Ferry JA, Hochberg EP, Huang MS, Iafrate AJ, Lara
DO, Pinkus GS, Salaverria I, et al: Pediatric-type nodal follicular
lymphoma: An indolent clonal proliferation in children and adults
with high proliferation index and no BCL2 rearrangement. Blood.
120:2395–2404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Araf S, Okosun J, Koniali L, Fitzgibbon J
and Heward J: Epigenetic dysregulation in follicular lymphoma.
Epigenomics. 8:77–84. 2016. View Article : Google Scholar :
|
|
49
|
Braggio E, Egan JB, Fonseca R and Stewart
AK: Lessons from next-generation sequencing analysis in
hematological malignancies. Blood Cancer J. 3:e1272013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kotsiou E, Okosun J, Besley C, Iqbal S,
Matthews J, Fitzgibbon J, Gribben JG and Davies JK: TNFRSF14
aberrations in follicular lymphoma increase clinically significant
allogeneic T-cell responses. Blood. 128:72–81. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Carbone PP, Kaplan HS, Musshoff K,
Smithers DW and Tubiana M: Report of the committee on Hodgkin's
disease staging classification. Cancer Res. 31:1860–1861.
1971.PubMed/NCBI
|
|
52
|
Armitage JO and Weisenburger DD: New
approach to classifying non-Hodgkin's lymphomas: Clinical features
of the major histo-logic subtypes. Non-Hodgkin's lymphoma
classification project. J Clin Oncol. 16:2780–2795. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Horning SJ and Rosenberg SA: The natural
history of initially untreated low-grade non-Hodgkin's lymphomas. N
Engl J Med. 311:1471–1475. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Takata K, Miyata-Takata T, Sato Y and
Yoshino T: Pathology of follicular lymphoma. J Clin Exp Hematop.
54:3–9. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nathwani BN: A promising new biologic
prognostic model in diffuse large B-cell lymphoma. Blood.
120:2161–2162. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pezella F, Jones M, Ralfkiaer E, Ersbøll
J, Gatter KC and Mason DY: Evaluation of bcl-2 protein expression
and 14;18 translocation as prognostic markers in follicular
lymphoma. Br J Cancer. 65:87–89. 1992. View Article : Google Scholar
|
|
57
|
Tomita N, Takasaki H, Miyashita K,
Fujisawa S, Ogusa E, Matsuura S, Kishimoto K, Numata A, Fujita A,
Ohshima R, et al: R-CHOP therapy alone in limited stage diffuse
large B-cell lymphoma. Br J Haematol. 161:383–388. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Siddhartha G and Vijay P: R-CHOP versus
R-CVP in the treatment of follicular lymphoma: A meta-analysis and
critical appraisal of current literature. J Hematol Oncol.
2:142009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Press OW, Unger JM, Rimsza LM, Friedberg
JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal
AK, et al: A comparative analysis of prognostic factor models for
follicular lymphoma based on a phase III trial of CHOP-rituximab
versus CHOP + 131iodine-tositumomab. Clin Cancer Res. 19:6624–6632.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kahl BS and Yang DT: Follicular lymphoma:
Evolving therapeutic strategies. Blood. 127:2055–2063. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Maloney DG, Grillo-López AJ, White CA,
Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles
TM, Dallaire BK, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal
antibody therapy in patients with relapsed low-grade non-Hodgkin's
lymphoma. Blood. 90:2188–2195. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
McLaughlin P, Grillo-López AJ, Link BK,
Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I,
White CA, Cabanillas F, et al: Rituximab chimeric anti-CD20
monoclonal antibody therapy for relapsed indolent lymphoma: Half of
patients respond to a four-dose treatment program. J Clin Oncol.
16:2825–2833. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Cang S, Iragavarapu C, Savooji J, Song Y
and Liu D: ABT-199 (venetoclax) and BCL-2 inhibitors in clinical
development. J Hematol Oncol. 8:1292015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Jazirehi AR and Bonavida B: Cellular and
molecular signal transduction pathways modulated by rituximab
(rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in
chemosensitization and therapeutic intervention. Oncogene.
24:2121–2143. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Alas S, Emmanouilides C and Bonavida B:
Inhibition of interleukin 10 by rituximab results in
down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's
lymphoma to apoptosis. Clin Cancer Res. 7:709–723. 2001.PubMed/NCBI
|
|
66
|
Leich E, Hoster E, Wartenberg M, Unterhalt
M, Siebert R, Koch K, Klapper W, Engelhard M, Puppe B, Horn H, et
al: Similar clinical features in follicular lymphomas with and
without breaks in the BCL2 locus. Leukemia. 30:854–860. 2016.
View Article : Google Scholar
|
|
67
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Watanabe R, Tomita N, Matsumoto C, Hattori
Y, Matsuura S, Takasaki H, Hashimoto C, Fujita H, Fujisawa S and
Ishigatsubo Y: The 3q27 and 18q21 translocations for follicular
lymphoma and diffuse large B-cell lymphoma in the rituximab era. J
Clin Exp Hematop. 53:107–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Goodlad JR, Batstone PJ, Hamilton DA,
Kernohan NM, Levison DA and White JM: BCL2 gene abnormalities
define distinct clinical subsets of follicular lymphoma.
Histopathology. 49:229–241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wong YP, Faridah AR, Ahmad Toha S and
Noraidah M: A case of t(14;18)-negative follicular lymphoma with
unusual immunopheno-type: A diagnostic dilemma. Med Health. 6(1
Suppl): S2072011.
|
|
71
|
Nybakken GE, Bala R, Gratzinger D, Jones
CD, Zehnder JL, Bangs CD, Cherry A, Warnke RA and Natkunam Y:
Isolated follicles enriched for centroblasts and lacking
t(14;18)/BCL2 in lymphoid tissue: Diagnostic and clinical
implications. PLoS One. 11:e01517352016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kamatani T, Mishima K, Kutsuna T,
Yoshihama Y, Kondo S and Shintani S: A case of surgical treatment
for primary BCL2-'negative' follicular lymphoma without t(14;18) in
early stage of the submandibular lymph node. J Oral Maxillofac Surg
Med Pathol. 26:599–602. 2014. View Article : Google Scholar
|
|
73
|
Cardenas MG, Yu W, Beguelin W, Teater MR,
Geng H, Goldstein RL, Oswald E, Hatzi K, Yang SN, Cohen J, et al:
Rationally designed BCL6 inhibitors target activated B cell diffuse
large B cell lymphoma. J Clin Invest. 126:3351–3362. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Ahearn IM, Haigis K, Bar-Sagi D and
Philips MR: Regulating the regulator: Post-translational
modification of RAS. Nat Rev Mol Cell Biol. 13:39–51. 2012.
View Article : Google Scholar
|
|
75
|
Bouska A, McKeithan TW, Deffenbacher KE,
Lachel C, Wright GW, Iqbal J, Smith LM, Zhang W, Kucuk C, Rinaldi
A, et al: Genome-wide copy-number analyses reveal genomic
abnormalities involved in transformation of follicular lymphoma.
Blood. 123:1681–1690. 2014. View Article : Google Scholar :
|
|
76
|
Li H, Kaminski MS, Li Y, Yildiz M,
Ouillette P, Jones S, Fox H, Jacobi K, Saiya-Cork K, Bixby D, et
al: Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2
(POU2F2); IRF8; and ARID1A underlying the pathogenesis of
follicular lymphoma. Blood. 123:1487–1498. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Migliazza A, Martinotti S, Chen W, Fusco
C, Ye BH, Knowles DM, Offit K, Chaganti RS and Dalla-Favera R:
Frequent somatic hypermutation of the 5' noncoding region of the
BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci USA.
92:12520–12524. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Alhejaily A, Day AG, Feilotter HE, Baetz T
and Lebrun DP: Inactivation of the CDKN2A tumor-suppressor gene by
deletion or methylation is common at diagnosis in follicular
lymphoma and associated with poor clinical outcome. Clin Cancer
Res. 20:1676–1686. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Cheung KJ, Johnson NA, Affleck JG,
Severson T, Steidl C, Ben-Neriah S, Schein J, Morin RD, Moore R,
Shah SP, et al: Acquired TNFRSF14 mutations in follicular lymphoma
are associated with worse prognosis. Cancer Res. 70:9166–9174.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Fitzgibbon J, Iqbal S, Davies A, O'Shea D,
Carlotti E, Chaplin T, Matthews J, Raghavan M, Norton A, Lister TA
and Young BD: Genome-wide detection of recurring sites of
uniparental disomy in follicular and transformed follicular
lymphoma. Leukemia. 21:1514–1520. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Oricchio E, Ciriello G, Jiang M, Boice MH,
Schatz JH, Heguy A, Viale A, de Stanchina E, Teruya-Feldstein J,
Bouska A, et al: Frequent disruption of the RB pathway in indolent
follicular lymphoma suggests a new combination therapy. J Exp Med.
211:1379–1391. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Pasqualucci L, Khiabanian H, Fangazio M,
Vasishtha M, Messina M, Holmes AB, Ouillette P, Trifonov V, Rossi
D, Tabbò F, et al: Genetics of follicular lymphoma transformation.
Cell Rep. 6:130–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Ross CW, Ouillette PD, Saddler CM, Shedden
KA and Malek SN: Comprehensive analysis of copy number and allele
status identifies multiple chromosome defects underlying follicular
lymphoma pathogenesis. Clin Cancer Res. 13:4777–4785. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Schwaenen C, Viardot A, Berger H, Barth
TF, Bentink S, Döhner H, Enz M, Feller AC, Hansmann ML, Hummel M,
et al: Microarray-based genomic profiling reveals novel genomic
aberrations in follicular lymphoma which associate with patient
survival and gene expression status. Genes Chromosomes Cancer.
48:39–54. 2009. View Article : Google Scholar
|
|
85
|
Ogura M, Ando K, Suzuki T, Ishizawa K, Oh
SY, Itoh K, Yamamoto K, Au WY, Tien HF, Matsuno Y, et al: A
multicentre phase II study of vorinostat in patients with relapsed
or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell
lymphoma. Br J Haematol. 165:768–776. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Okosun J, Bödör C, Wang J, Araf S, Yang
CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, et al: Integrated
genomic analysis identifies recurrent mutations and evolution
patterns driving the initiation and progression of follicular
lymphoma. Nat Genet. 46:176–181. 2014. View Article : Google Scholar :
|
|
87
|
Krajnovic M, Radojkovic M, Davidovic R,
Dimitrijevic B and Krtolica K: Prognostic significance of
epigenetic inactivation of p16, p15, MGMT and DAPK genes in
follicular lymphoma. Med Oncol. 30:4412013. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Morin RD, Mendez-Lago M, Mungall AJ, Goya
R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field
M, et al: Frequent mutation of histone-modifying genes in
non-Hodgkin lymphoma. Nature. 476:298–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Morin RD, Johnson NA, Severson TM, Mungall
AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, et
al: Somatic mutations altering EZH2 (Tyr641) in follicular and
diffuse large B-cell lymphomas of germinal-center origin. Nat
Genet. 42:181–185. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
90
|
Grønbaek K, Straten PT, Ralfkiaer E,
Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K and
Guldberg P: Somatic Fas mutations in non-Hodgkin's lymphoma:
Association with extranodal disease and autoimmunity. Blood.
92:3018–3024. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Xia Q, Wang G, Wang H, Hu Q and Ying Z:
Folliculin, a tumor suppressor associated with Birt-Hogg-Dube (BHD)
syndrome, is a novel modifier of TDP-43 cytoplasmic translocation
and aggregation. Hum Mol Genet. 25:83–96. 2016. View Article : Google Scholar
|
|
92
|
Limpens J, Stad R, Vos C, de Vlaam C, de
Jong D, van Ommen GJ, Schuuring E and Kluin PM: Lymphoma-associated
translocation t(14;18) in blood B cells of normal individuals.
Blood. 85:2528–2536. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhu D, McCarthy H, Ottensmeier CH, Johnson
P, Hamblin TJ and Stevenson FK: Acquisition of potential
N-glycosylation sites in the immunoglobulin variable region by
somatic mutation is a distinctive feature of follicular lymphoma.
Blood. 99:2562–2568. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Chim CS, Wong KY, Loong F and Srivastava
G: SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and
follicular lymphoma: Implications for epigenetic activation of the
Jak/STAT pathway. Leukemia. 18:356–358. 2004. View Article : Google Scholar
|
|
95
|
Koyama M, Oka T, Ouchida M, Nakatani Y,
Nishiuchi R, Yoshino T, Hayashi K, Akagi T and Seino Y: Activated
proliferation of B-cell lymphomas/leukemias with the SHP1 gene
silencing by aberrant CpG methylation. Lab Invest. 83:1849–1858.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Oka T, Yoshino T, Hayashi K, Ohara N,
Nakanishi T, Yamaai Y, Hiraki A, Sogawa CA, Kondo E, Teramoto N, et
al: Reduction of hematopoietic cell-specific tyrosine phosphatase
SHP-1 gene expression in natural killer cell lymphoma and various
types of lymphomas/leukemias: Combination analysis with cDNA
expression array and tissue microarray. Am J Pathol. 159:1495–1505.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Honma K, Tsuzuki S, Nakagawa M, Tagawa H,
Nakamura S, Morishima Y and Seto M: TNFAIP3/A20 functions as a
novel tumor suppressor gene in several subtypes of non-Hodgkin
lymphomas. Blood. 114:2467–2475. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Kato M, Sanada M, Kato I, Sato Y, Takita
J, Takeuchi K, Niwa A, Chen Y, Nakazaki K, Nomoto J, et al:
Frequent inactivation of A20 in B-cell lymphomas. Nature.
459:712–716. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Mottok A, Rennè C, Seifert M, Oppermann E,
Bechstein W, Hansmann ML, Küppers R and Bräuninger A: Inactivating
SOCS1 mutations are caused by aberrant somatic hypermutation and
restricted to a subset of B-cell lymphoma entities. Blood.
114:4503–4506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Cheung KJ, Delaney A, Ben-Neriah S, Schein
J, Lee T, Shah SP, Cheung D, Johnson NA, Mungall AJ, Telenius A, et
al: High resolution analysis of follicular lymphoma genomes reveals
somatic recurrent sites of copy-neutral loss of heterozygosity and
copy number alterations that target single genes. Genes Chromosomes
Cancer. 49:669–681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Launay E, Pangault C, Bertrand P, Jardin
F, Lamy T, Tilly H, Tarte K, Bastard C and Fest T: High rate of
TNFRSF14 gene alterations related to 1p36 region in de novo
follicular lymphoma and impact on prognosis. Leukemia. 26:559–562.
2012. View Article : Google Scholar
|
|
102
|
O'Shea D, O'Riain C, Taylor C, Waters R,
Carlotti E, Macdougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM,
et al: The presence of TP53 mutation at diagnosis of follicular
lymphoma identifies a high-risk group of patients with shortened
time to disease progression and poorer overall survival. Blood.
112:3126–3129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Sander CA, Yano T, Clark HM, Harris C,
Longo DL, Jaffe ES and Raffeld M: p53 mutation is associated with
progression in follicular lymphoma. Blood. 82:1994–2004. 1993.
View Article : Google Scholar : PubMed/NCBI
|
